温补脾肾经验方治疗视神经脊髓炎谱系疾病作用机制的网络药理学分析

doi:10.13481/j.1671-587X.20230201

Abstract

Abstract:

Objective To discuss the potential targets and signaling pathways of Tonifying Slpeen and Kidney Empirical Prescription （TSKEP） in the treatment of neuromyelitis optica spectrum disorders（NMOSD） through network pharmacology analysis and animal experiment，and to provide the theoretical basis for the treatment of NMOSD. Method Traditional Chinese Medicine System Analysis Platform（TCMSP） Database was used to screen the chemical compounds and targets of TSKEP； the related target genes in NMOSD were comfirmed through GendCard and other Databases；the core compounds were obtained by building the compound-target network； the STRING Database and the Network Analyzer plugin in Cytoscape 3.6.0 software were used to obtain the topology parameters of protein-protein interaction （PPI） network and to identify the core targets； Omicshare platform was used to perform the Geno Ontology （GO） and Kyoto Encyclopedia of Genes and Genomes（KEGG） pathway enrichment analysis and the target-pathway network was conducted to identify core key biological processes and signaling pathways； the molecular docking of core compounds and core targets was performed based on AutoDock software. Eighteen mice were divided into control group， NMOSD group， and TSKEP group， and there were 6 mice in each group. The morphology of brain tissue of the mice in various groups were observed by HE staining，and the levels of related cytokines in serum of the mice were detected by enzyme-linked immunosorbent assay（ELISA） method. Results The animal experiment results showed that compared with NMOSD group，the score of neural function defect of the mice in TSKEP group was decreased（P<0.01）， and the degree of inflammatory cell infiltration in central nervous system of the mice in TSKEP group was allevited. A total of 304 active compounds and 655 drug targets were screened， and 43 potential targets were related to the treatment of NMOSD with TSKEP. Quercetin， luteolin， and stigmasterol may be the core compounds，and interleukin-6（IL-6），interlleukin-1β（IL-1β），tumor necrosis factor-α（TNF-α） could be the poetential core targets.The KEGG pathway enrichment analysis and network analysis results showed that TSKEP may play an important role in the treatment of NMOSD through 14 signaling pathways.The molecular docking verification results showed that core compounds combined well with the core targets. Compared with NMOSD group and control group， the levels of serum inflammatory cytokines of the mice in TSKEP group were decreased（P<0.05 or P<0.01）. Conclusion Based on the verification of network pharmacology and animal experiment， TSKEP can exert the therapeutic effect through regulating the expressions of serum inflammatory cytokines， promoting the repairment and regeneration of nerve function，and reducing the inflammatory response of the central nervous system by multiple targets and signaling pathways.

Key words: Neuromyelitis optica spectrum disorders, Tonifying Slpeen and Kidney Empirical Prescription, Network pharmacology, Molecular docking

CLC Number:

R744.52

Yushuang GONG,Yefan FU,Huijing XU,Jian GUO,Lin XIANG,Rui HU,Rui FAN,Jie WANG,Miao LI,Meiyan SUN. Network pharmacology analysis on mechanism of Tonifying Slpeen and Kidney Empirical Prescription in treatment of neuromyelitis optica spectrum disorders[J].Journal of Jilin University(Medicine Edition), 2023, 49(2): 261-271.

Figures/Tables 9

Fig. 1

Fig. 2

Fig. 3

Tab. 1

Fig. 4

Tab.2

Fig. 5

Fig. 6

Fig.7

References 41

1	PALACE J， LIN D Y， ZENG D L， et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders［J］. Brain， 2019， 142（5）： 1310-1323.
2	WALLACH A I， TREMBLAY M， KISTER I. Advances in the treatment of neuromyelitis optica spectrum disorder［J］. Neurol Clin， 2021， 39（1）： 35-49.
3	ALROUGHANI R， QADI N， INSHASI J， et al. Neuromyelitis optica spectrum disorders in the Arabian Gulf： chall enges and growing experience［J］. Mult Scler J Exp Transl Clin，2020，6（1）：2055217319850195.
4	马振，赵凰宏，关东升，等. 张磊治疗视神经脊髓炎临证经验［J］. 中国中医基础医学杂志， 2021， 27（8）： 1319-1321.
5	骆书庆，赵铎，潘亚茹. 37例视神经脊髓炎谱系疾病中医证候分布规律及临床特点的研究［J］. 中医研究， 2019， 32（6）： 39-42.
6	徐全刚，王晓辉，黄德晖，等.MOG-（35-55）诱发实验性自身免疫性脑脊髓炎小鼠模型［J］.中华神经医学杂志，2006（2）：141-144.
7	CHAN K H， ZHANG R， KWAN J S C， et al. Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse［J］. J Neuroimmunol， 2012， 245（1-2）： 32-38.
8	LUO J Y， XIE C， ZHANG W， et al. Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice［J］. Mult Scler Relat Disord， 2020， 46： 102473.
9	徐叔云. 药理实验方法学［M］. 3版. 北京：人民卫生出版社， 2002： 882-928.
10	WANG K C， TSAI C P， LEE C L， et al. α-Lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-γ to ameliorate experimental autoimmune encephalomyelitis in mice ［J］. Clin Sci， 2013， 125（7）： 329-340.
11	RU J L， LI P， WANG J N， et al. TCMSP： a database of systems pharmacology for drug discovery from herbal medicines［J］. J Cheminform， 2014， 6： 13.
12	PAN B Y， SHI X N， DING T T， et al. Unraveling the action mechanism of polygonum cuspidatum by a network pharmacology approach［J］. Am J Transl Res， 2019， 11（11）： 6790-6811.
13	SZKLARCZYK D， GABLE A L， LYON D， et al. STRING v11： protein-protein association networks with increased coverage， supporting functional discovery in genome-wide experimental datasets［J］. Nucleic Acids Res， 2019， 47（D1）： D607-D613.
14	PIÑERO J， RAMÍREZ-ANGUITA J M， SAÜCH-PITARCH J， et al. The DisGeNET knowledge platform for disease genomics： 2019 update［J］. Nucleic Acids Res， 2020， 48（D1）： D845-D855.
15	SAFRAN M， DALAH I， ALEXANDER J， et al. GeneCards version 3： the human gene integrator［J］. Database （Oxford）， 2010， 2010： baq020.
16	AMBERGER J S， BOCCHINI C A， SCOTT A F，et al.OMIM.org： leveraging knowledge across phenotype-gene relationships［J］.Nucleic Acids Res，2019，47（D1）： D1038-D1043.
17	WISHART D S， FEUNANG Y D， GUO A C， et al. DrugBank 5.0： a major update to the DrugBank database for 2018［J］. Nucleic Acids Res， 2018， 46（D1）： D1074-D1082.
18	GUO X， JI J Y， FENG Z T， et al. A network pharmacology approach to explore the potential targets underlying the effect of sinomenine on rheumatoid arthritis［J］. Int Immunopharmacol， 2020， 80： 106201.
19	MU J， ZHANG S， TANG F F， et al. Mechanism underlying effect of Chaihu Shugan San on major depressive disorder： a network pharmacology-based study［J］. J Tradit Chin Med， 2021， 41（2）： 338-348.
20	WANG R Y， LIN J T. Analysis of the mechanism of zhichuanling oral liquid in treating bronchial asthma based on network pharmacology［J］. Evid Based Complement Alternat Med， 2020， 2020： 1875980.
21	BERMAN H M， WESTBROOK J， FENG Z K， et al. The protein data bank［J］. Nucleic Acids Res， 2000， 28（1）： 235-242.
22	KIM S， CHEN J， CHENG T J， et al. PubChem in 2021： new data content and improved web interfaces［J］. Nucleic Acids Res， 2021， 49（D1）： D1388-D1395.
23	李昀泽，姚阳婧，顾锡镇，等. 基于顾锡镇教授学术思想创立扶元通督饮治疗视神经脊髓炎谱系疾病临床经验探析［J］. 河北中医， 2019， 41（10）： 1445-1450.
24	于佳，孙雅琴，赵晖，等. 槲皮素促进CPZ诱导脱髓鞘模型小鼠髓鞘再生的作用机制研究［J］. 国际中医中药杂志， 2020， 42（1）： 39-45.
25	蔡智谋，王晓慧，蒋冰之，等. 槲皮素免疫学作用研究进展［J］. 教育教学论坛， 2016（16）： 83-84.
26	李佳睿，耿菲，赵业宁，等. 核壳温敏型药物载体负载槲皮素对SiO₂诱导的大鼠巨噬细胞极化的抑制作用［J］.郑州大学学报（医学版），2023，58（2）：182-186.
27	李昕，刘佳佳，何浩，等. 槲皮素对LPS诱导的中性粒细胞产生白介素6的影响［J］. 免疫学杂志， 2006，22（1）： 40-42， 46.
28	陈元堃，曾奥，罗振辉，等. β-谷甾醇药理作用研究进展［J］. 广东药科大学学报， 2021， 37（1）： 148-153.
29	周志远，卢群，刘洋，等. 豆甾醇的研究及开发进展［J］. 中国当代医药， 2015， 22（24）： 15-17.
30	于倩，巫冠中. 木犀草素抗炎机制的研究进展［J］. 药学研究， 2019， 38（2）： 108-111， 119.
31	NATAF S. The demonstration of an Aqp4/tgf-beta 1 pathway in murine astrocytes holds implications for both neuromyelitis optica and progressive multiple sclerosis［J］. Int J Mol Sci， 2020， 21（3）： 1035.
32	LEVY M. Interleukin-6 receptor blockade for the treatment of NMOSD［J］. Lancet Neurol， 2020， 19（5）： 370-371.
33	MIHARA M， NISHIMOTO N， OHSUGI Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody［J］.Expert Opin Biol Ther，2005，5（5）： 683-690.
34	KONG B S， KIM Y， KIM G Y， et al. Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder［J］.J Neuroinflammat， 2017， 14（1）： 191.
35	BARROS P O， CASSANO T， HYGINO J， et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin （IL）-6 produced during remission phase［J］. Clin Exp Immunol， 2016， 183（3）： 480-489.
36	段正昊，崔文琪，冯娟. 抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病的临床研究进展［J］.中国实用内科杂志，2021，41（10）：890-894.
37	王静文，杨涛，仝延萍，等. 补肾益髓胶囊对缓解期视神经脊髓炎患者外周血上皮嗜中性粒细胞活化肽78表达水平的影响［J］. 中华中医药杂志， 2019， 34（3）： 1284-1286.
38	李康宁，王蕾，于佳佳，等. 基于网络药理学的补肾益髓胶囊治疗多发性硬化机制研究［J］. 中国中医药信息杂志， 2019， 26（5）： 98-104.
39	KANEHISA M， SATO Y， KAWASHIMA M， et al. KEGG as a reference resource for gene and protein annotation［J］. Nucleic Acids Res， 2016，44（D1）：D457-D462.
40	GRAUMANN U， REYNOLDS R， STECK A J， et al. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult［J］. Brain Pathol， 2003， 13（4）： 554-573.
41	ZHANG Z Y， YI P J， YANG J J， et al. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer’s disease［J］. J Ethnopharmacol， 2020， 249： 112371.

MOL ID	Compound	Degree	OB(η/%)	DL	CC
MOL000098	Quercetin	870	46.43	0.28	0.42
MOL000422	Kaempferol	171	41.88	0.24	0.38
MOL000449	Stigmasterol	162	43.83	0.76	0.37
MOL000050	GLY	110	48.74	0.00	0.38
MOL000008	Apigenin	75	23.06	0.21	0.37
MOL000390	Daidzein	64	19.44	0.19	0.36
MOL008583	beta-sitosterol	63	36.91	0.75	0.37
MOL000006	Luteolin	55	36.16	0.25	0.36
MOL000069	palmitic acid	52	19.30	0.10	0.35
MOL000785	palmatine	48	64.6	0.65	0.35
MOL001454	Berberine	45	36.86	0.78	0.35
MOL008400	glycitein	42	50.48	0.24	0.34

KEGG metabolic pathway	Number of gene	P
Cytokine-cytokine receptor interaction	14	5.47×10^－11
Toll-like receptor signaling pathway	10	8.48×10^－11
IL-17 signaling pathway	9	6.15×10^－10
TNF signaling pathway	9	3.83×10^－9
Jak-STAT signaling pathway	9	3.47×10^－8
NF-kappa B signaling pathway	8	6.60×10^－8
C-type lectin receptor signaling pathway	6	1.09×10^－5
Intestinal immune network for IgA production	6	1.45×10^－5
PI3K-Akt signaling pathway	9	2.90×10^－5
Human cytomegalovirus infection	8	4.96×10^－5
T cell receptor signaling pathway	5	<0.01
HTLV-Ⅰ infection	8	<0.01
Th17 cell differentiation	5	<0.01
MAPK signaling pathway	6	<0.01

[1]	Zhouquan LI,Hui LI,Ying TANG,Lijun YANG,Yinghong JIANG,Lipin YIN. Network pharmacology and molecular docking analysis on mechanism of Tongluo Tangtai Power in treatment of diabetic peripheral neuropathy [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 341-350.
[2]	Minghui WANG,Moyi LIU,Helin WANG,Ying LI,Xiangjun WANG,Hetong HUI,Xinyuan FAN,Tianqi WANG,Limei LIU. Bioinformatics analysis of network pharmacology and molecular docking technology based on mechanism of Physalis Calyx seu Fructus on leukemia [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 74-83.
[3]	Shaojie FU,Sensen SU,Yiying CHEN,Zhonggao XU. Analysis on network pharmacology and molecular docking technique based on mechanism of Shenqi Dihuang Decoction in treatment of membranous nephropathy [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1518-1527.
[4]	Yan LI,Yue HOU,Xingwei MU,Bingqing LIU,Hong WAN,Chang LIU,Wei XIA. Network pharmacology and molecular docking analysis on mechanism of Schisandrae Chinensis Fructus in occurrence and development of thoracic aortic aneurysm [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 414-425.
[5]	ZHI Dingming, SUI Dianjun, QI Rui, MIAO Yongdi, HAN Dong, LOU Shilei, QIU Yue, SUN Cong. Potential targets of pueraria in treatment of hyperlipoproteinemia based on network pharmacology [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 724-730.

Network pharmacology analysis on mechanism of Tonifying Slpeen and Kidney Empirical Prescription in treatment of neuromyelitis optica spectrum disorders

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 41

Related Articles 5

Metrics

Comments

Recommended 0